Ann: Mesoblast Update on COVID-19 ARDS Trial, page-267

disclosure,sometimes I am seen as a down ramper here, because I think SI management team is a failure.
staying technical. just picked up shares at 2.2
feels like all failures for msb in all fronts. so the sp should be at less than 1.
but. when is the right time to buy this stock? perhaps now.
A long leg on the chart today could not have been easy to achieve.
did we really expect msb will come up with a magic cure for covid?
what if the reduction of mortality is 30%? 20%? 10%?
if it works for kids with leaukimia, why not in adults?
Ards are essentially the same.
Even CHF trial, I think the market has got it wrong. someone who had a heart attack, will always have problems on and off. 60% reduction in mortality, paves way for it being part of a treatment package in the future.
prophets always stand alone.